Straumann Holding AGXSWX:STMN +1.81%99 ROE % is 11.33% as of Dec. 2025, which is 53% below its 10-year median of 23.93. GuruFocus rates XSWX:STMN with a GF Score™ of 99/100 and a GF Value™ of CHF136.92 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Straumann Holding AG ranks better than 88.86% on this metric.
The historical rank and industry rank for Straumann Holding AG's ROE % or its related term are showing as below:
XSWX:STMN'
s ROE % Range Over the Past 10 Years
Min: 7.11 Med: 23.93 Max: 37.07
Current: 17.06
During the past 13 years, Straumann Holding AG's highest ROE % was 37.07%. The lowest was 7.11%. And the median was 23.93%.
XSWX:STMN's ROE % is ranked better than 88.86% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs XSWX:STMN: 17.06
Straumann Holding AG (XSWX:STMN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's ROE % distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Straumann Holding AG (XSWX:STMN) has a ROE % of 11.33% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Straumann Holding AG and its competitors. This is 53% below median its historical median of 23.93. Over the past decade, Straumann Holding AG's ROE % has ranged from 7.11 to 37.07. According to the industry distribution chart, Straumann Holding AG ranks #89 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 11.1%.
Is Straumann Holding AG's ROE % too high?
Straumann Holding AG's current ROE % of 11.33% is 53% below median its 10-year median of 23.93. Over the past 10 years, this metric has ranged from a low of 7.11 to a high of 37.07. The Medical Devices & Instruments industry median ROE % is 2.42. Straumann Holding AG's value of 11.33% is 368.2% above this industry median. Based on the distribution chart, Straumann Holding AG ranks #89 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Straumann Holding AG has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #89 out of 799 companies for ROE %. This places Straumann Holding AG in the top 11% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Straumann Holding AG's value of 11.33% is 368.2% above this benchmark. Historically, Straumann Holding AG's own ROE % has ranged from 7.11 to 37.07 over the past decade. While the company's 10-year median is 23.93 vs. the industry median of 2.42, Straumann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current ROE % of 11.33% is 368.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current ROE % is 11.33%, which is 53% below median its own 10-year median of 23.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF136.92, compared to a current price of CHF106.80 — trading 22% below its estimated fair value. The current ROE % is 11.33%, which is 53% below median its 10-year median of 23.93 and 368.2% above the Medical Devices & Instruments industry median of 2.42. Straumann Holding AG's overall GF Score™ is 99/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current ROE % is 11.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF106.80 is trading 22% below its estimated GF Value™ of CHF136.92.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
ROE %: 11.33% (53% below median its 10-year median of 23.93)
GF Value™: CHF136.92 vs. price of CHF106.80 (22% below fair value)
Industry Position: 368.2% above the Medical Devices & Instruments median (#89 of 799)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
99GF Score
Get the complete analysis for XSWX:STMN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
